{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T07:24:12Z","timestamp":1747207452433,"version":"3.40.5"},"reference-count":63,"publisher":"Bentham Science Publishers Ltd.","issue":"1","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["DML"],"published-print":{"date-parts":[[2021,5,5]]},"abstract":"<jats:sec>\n<jats:title> Purpose:<\/jats:title>\n<jats:p>Previous studies have shown that catabolism of adenosine 5\u2019-triphosphate\n(ATP) in systemic blood is a potential surrogate biomarker for cardiovascular toxicity. We compared\nthe acute toxicity of high doses of doxorubicin (DOX) and isoproterenol (ISO) on hemodynamics\nand ATP catabolism in the systemic circulation.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>sprague Dawley (SD) rats (n = 8 - 11) were each given either a single dose of 30 mg\/kg\nISO, or a twice-daily dose of 10 mg\/kg of DOX or 4 doses of normal saline (control) by subcutaneous\ninjection. Blood samples were collected up to 6 hours for measuring concentrations of ATP\nand its catabolites. Hemodynamics was recorded continuously. The difference was considered significant\nat p &lt; 0.05 (ANOVA).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p>Mortality was 1\/8, 5\/11, and 0\/11 for the DOX, ISO, and control groups, respectively. Systolic\nblood pressure was significantly lower in the DOX and ISO treated rats than in control measured\nat the last recorded time (76 \u00b1 9 for DOX vs. 42 \u00b1 8 for ISO vs. 103 \u00b1 5 mmHg for control, p\n&lt; 0.05 for all). Blood pressure fell gradually after the final injection for both DOX and control\ngroups, but abruptly after ISO, followed by a rebound and then gradual decline till the end of the\nexperiment. Heart rate was significantly higher after ISO, but there were no differences between\nthe DOX and control rats (p &gt; 0.05). RBC concentrations of ADP and AMP, and plasma concentrations\nof adenosine and uric acid were significantly higher in the ISO group. In contrast, hypoxanthine\nconcentrations were significantly higher in the DOX treated group (p &lt; 0.05).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusion:<\/jats:title>\n<jats:p>Acute cardiovascular toxicity induced by DOX and ISO may be measured by changes\nin hemodynamics and breakdown of ATP and adenosine in the systemic circulation, albeit a\nnotable qualitative and quantitative difference was observed.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1872312814666201022103802","type":"journal-article","created":{"date-parts":[[2020,10,23]],"date-time":"2020-10-23T04:15:32Z","timestamp":1603426532000},"page":"80-88","update-policy":"https:\/\/doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hemodynamic Assessment and In vivo Catabolism of Adenosine 5\u2019-triphosphate in Doxorubicin or Isoproterenol-induced Cardiovascular Toxicity"],"prefix":"10.2174","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0517-104X","authenticated-orcid":true,"given":"Pollen K.","family":"Yeung","sequence":"first","affiliation":[{"name":"Pharmacokinetics and Metabolism Laboratory, College of Pharmacy and Department of Medicine, Faculties of Health and Medicine, Dalhousie University, Halifax, NS, C B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheyda","family":"Mohammadizadeh","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Metabolism Laboratory, College of Pharmacy and Department of Medicine, Faculties of Health and Medicine, Dalhousie University, Halifax, NS, C B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fatemeh","family":"Akhoundi","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Metabolism Laboratory, College of Pharmacy and Department of Medicine, Faculties of Health and Medicine, Dalhousie University, Halifax, NS, C B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelsey","family":"Mann","sequence":"additional","affiliation":[{"name":"Pharmacokinetics and Metabolism Laboratory, College of Pharmacy and Department of Medicine, Faculties of Health and Medicine, Dalhousie University, Halifax, NS, C B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Remigius U.","family":"Agu","sequence":"additional","affiliation":[{"name":"Biopharmaceutics and Drug Delivery Laboratory, College of Pharmacy, Faculty of Health, Dalhousie University, Halifax, NS, C B3H 4R2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Pulinilkunnil","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Department of Biochemistry and Molecular Biology, Dalhousie University, Dalhousie Medicine New Brunswick, Saint John, NB E2K 5E2, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"893","DOI":"10.1161\/01.CIR.85.3.893","volume":"85","author":"Ely S.W.","year":"1992","unstructured":"Ely S.W.; Berne R.M.; Protective effects of adenosine in myocardial ischemia. Circulation 1992,85(3),893-904","journal-title":"Circulation"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1161\/hq0302.105360","volume":"22","author":"Burnstock G.","year":"2002","unstructured":"Burnstock G.; Purinergic signaling and vascular cell proliferation and death. Arterioscler Thromb Vasc Biol 2002,22(3),364-373","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.3389\/fphar.2019.00098","volume":"10","author":"Johnson T.A.","year":"2019","unstructured":"Johnson T.A.; Jinnah H.A.; Kamatani N.; Shortage of Cellular ATP as a Cause of Diseases and Strategies to Enhance ATP. Front Pharmacol 2019,10,98","journal-title":"Front Pharmacol"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1161\/01.RES.47.6.807","volume":"47","author":"Berne R.M.","year":"1980","unstructured":"Berne R.M.; The role of adenosine in the regulation of coronary blood flow. Circ Res 1980,47(6),807-813","journal-title":"Circ Res"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"pp. 309","DOI":"10.1007\/978-3-642-45619-0","author":"Gerlach E.","year":"1987","unstructured":"Gerlach E.; Becker B.F.; Nees S.;  The Topic and Perspectives in Adenosine Research Gerlach, E; Becker, B F; Springer-Verlag: New York NY, 1987,pp. 309-320","journal-title":"The Topic and Perspectives in Adenosine Research Gerlach, E; Becker, B F; Springer-Verlag: New York NY,"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1007\/s00395-007-0687-7","volume":"103","author":"Cohen M.V.","year":"2008","unstructured":"Cohen M.V.; Downey J.M.; Adenosine: trigger and mediator of cardioprotection. Basic Res Cardiol 2008,103(3),203-215","journal-title":"Basic Res Cardiol"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S0100-879X2008005000037","volume":"42","author":"Burnstock G.","year":"2009","unstructured":"Burnstock G.; Purinergic signalling: past, present and future. Braz J Med Biol Res 2009,42(1),3-8","journal-title":"Braz J Med Biol Res"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1002\/iub.31","volume":"60","author":"Das M.","year":"2008","unstructured":"Das M.; Das D.K.; Molecular mechanism of preconditioning. IUBMB Life 2008,60(4),199-203","journal-title":"IUBMB Life"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"212","DOI":"10.3389\/fphar.2018.00212","volume":"9","author":"Dal Ben D.","year":"2018","unstructured":"Dal Ben D.; Antonioli L.; Lambertucci C.; Fornai M.; Blandizzi C.; Volpini R.; Purinergic Ligands as Potential Therapeutic Tools for the Treatment of Inflammation-Related Intestinal Diseases. Front Pharmacol 2018,9,212","journal-title":"Front Pharmacol"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"784","DOI":"10.3390\/ijms19030784","volume":"19","author":"Camici M.","year":"2018","unstructured":"Camici M.; Garcia-Gil M.; Tozzi M.G.; The Inside Story of Adenosine. Int J Mol Sci 2018,19(3),784","journal-title":"Int J Mol Sci"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/jcp.25944","volume":"233","author":"Bahreyni A.","year":"2018","unstructured":"Bahreyni A.; Samani S.S.; Rahmani F.; Behnam-Rassouli R.; Khazaei M.; Ryzhikov M.; Parizadeh M.R.; Avan A.; Hassanian S.M.; Role of adenosine signaling in the pathogenesis of breast cancer. J Cell Physiol 2018,233(3),1836-1843","journal-title":"J Cell Physiol"},{"key":"ref=12","first-page":"309","volume":"123","author":"Rounds S.","year":"1994","unstructured":"Rounds S.; Hsieh L.; Agarwal K.C.; Effects of endotoxin injury on endothelial cell adenosine metabolism. J Lab Clin Med 1994,123(2),309-317","journal-title":"J Lab Clin Med"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"219","DOI":"10.2174\/1872312810666160607013859","volume":"10","author":"Yeung P.K.","year":"2016","unstructured":"Yeung P.K.; Kolathuru S.S.; Agu R.U.; Effect of Cardiovascular Injury on Catabolism of Adenosine and Adenosine 5-'Triphosphate in Systemic Blood in a Freely Moving Rat Model In Vivo. Drug Metab Lett 2016,10(3),219-226","journal-title":"Drug Metab Lett"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.2174\/1874073101105010001","volume":"5","author":"Yeung P.","year":"2011","unstructured":"Yeung P.; Anti-Ischemia Drugs have no Effect on the In Vivo Metabolism of ATP by RBC in Normotensive Restrained Rats. Open Drug Metab J 2011,5,1","journal-title":"Open Drug Metab J"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"775","DOI":"10.3390\/metabo4030775","volume":"4","author":"Yeung P.K.","year":"2014","unstructured":"Yeung P.K.; Xu Z.; Seeto D.; Diltiazem reduces mortality and breakdown of ATP in red blood cell induced by isoproterenol in a freely moving rat model in vivo. Metabolites 2014,4(3),775-789","journal-title":"Metabolites"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1007\/s00421-010-1611-7","volume":"110","author":"Dudzinska W.","year":"2010","unstructured":"Dudzinska W.; Lubkowska A.; Dolegowska B.; Safranow K.; Jakubowska K.; Adenine, guanine and pyridine nucleotides in blood during physical exercise and restitution in healthy subjects. Eur J Appl Physiol 2010,110(6),1155-1162","journal-title":"Eur J Appl Physiol"},{"key":"ref=17","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1177\/1753944712470297","volume":"7","author":"Yeung P.K.","year":"2013","unstructured":"Yeung P.K.; Dauphinee J.; Marcoux T.; Effect of acute exercise on cardiovascular hemodynamic and red blood cell concentrations of purine nucleotides in hypertensive compared with normotensives rats. Ther Adv Cardiovasc Dis 2013,7(2),63-74","journal-title":"Ther Adv Cardiovasc Dis"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"20","DOI":"10.3390\/metabo8020030","volume":"8","author":"Yeung P.K.","year":"2018","unstructured":"Yeung P.K.; Kolathuru S.S.; Mohammadizadeh S.; Akhoundi F.; Linderfield B.; Adenosine 5\u2032-Triphosphate Metabolism in Red Blood Cells as a Potential Biomarker for Post-Exercise Hypotension and a Drug Target for Cardiovascular Protection. Metabolites 2018,8(2),20","journal-title":"Metabolites"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"102","DOI":"10.4172\/2329-6607.1000102","volume":"2","author":"Yeung P.","year":"2013","unstructured":"Yeung P.; Seeto D.; A study of the effect of isoproterenol on red blood cell concentrations of adenine nucleotides in a freely moving rat model in vivo. Cardiovas Pharmacol [Open Access].2013,2(1),102","journal-title":"Cardiovas Pharmacol"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1097\/FPC.0b013e32833ffb56","volume":"21","author":"Thorn C.F.","year":"2011","unstructured":"Thorn C.F.; Oshiro C.; Marsh S.; Hernandez-Boussard T.; McLeod H.; Klein T.E.; Altman R.B.; Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenet Genomics 2011,21(7),440-446","journal-title":"Pharmacogenet Genomics"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1159\/000265166","volume":"115","author":"Chatterjee K.","year":"2010","unstructured":"Chatterjee K.; Zhang J.; Honbo N.; Karliner J.S.; Doxorubicin cardiomyopathy. Cardiology 2010,115(2),155-162","journal-title":"Cardiology"},{"key":"ref=22","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1016\/j.tips.2015.03.005","volume":"36","author":"Rochette L.","year":"2015","unstructured":"Rochette L.; Guenancia C.; Gudjoncik A.; Hachet O.; Zeller M.; Cottin Y.; Vergely C.; Anthracyclines\/trastuzumab: new aspects of cardiotoxicity and molecular mechanisms. Trends Pharmacol Sci 2015,36(6),326-348","journal-title":"Trends Pharmacol Sci"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"795602","DOI":"10.1155\/2015\/795602","volume":"2015","author":"Angsutararux P.","year":"2015","unstructured":"Angsutararux P.; Luanpitpong S.; Issaragrisil S.; Chemotherapy-Induced Cardiotoxicity: Overview of the Roles of Oxidative Stress. Oxid Med Cell Longev 2015,2015,795602","journal-title":"Oxid Med Cell Longev"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1016\/j.jacbts.2019.07.009","volume":"5","author":"Sabbah H.N.","year":"2020","unstructured":"Sabbah H.N.; Targeting the Mitochondria in Heart\u00a0Failure: A Translational Perspective. JACC Basic Transl Sci 2020,5(1),88-106","journal-title":"JACC Basic Transl Sci"},{"key":"ref=25","doi-asserted-by":"publisher","first-page":"3769","DOI":"10.1042\/BCJ20160385","volume":"473","author":"Bartlett J.J.","year":"2016","unstructured":"Bartlett J.J.; Trivedi P.C.; Yeung P.; Kienesberger P.C.; Pulinilkunnil T.; Doxorubicin impairs cardiomyocyte viability by suppressing transcription factor EB expression and disrupting autophagy. Biochem J 2016,473(21),3769-3789","journal-title":"Biochem J"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"101394","DOI":"10.1016\/j.redox.2019.101394","volume":"29","author":"Kalyanaraman B.","year":"2020","unstructured":"Kalyanaraman B.; Teaching the basics of the mechanism of doxorubicin-induced cardiotoxicity: Have we been barking up the wrong tree? Redox Biol 2020,29,101394","journal-title":"Redox Biol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1007\/s40265-016-0592-1","volume":"76","author":"Lee H.Y.","year":"2016","unstructured":"Lee H.Y.; Oh B.H.; Fimasartan: A New Angiotensin Receptor Blocker. Drugs 2016,76(10),1015-1022","journal-title":"Drugs"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1111\/jcmm.12633","volume":"19","author":"Gu J.","year":"2015","unstructured":"Gu J.; Hu W.; Zhang D.D.; Resveratrol, a polyphenol phytoalexin, protects against doxorubicin-induced cardiotoxicity. J Cell Mol Med 2015,19(10),2324-2328","journal-title":"J Cell Mol Med"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1586\/14737140.2015.1047766","volume":"15","author":"Abdel-Rahman O.","year":"2015","unstructured":"Abdel-Rahman O.; Alorabi M.; Use of angiotensin-converting enzyme inhibitors in the prophylaxis of anthracycline or trastuzumab-related cardiac dysfunction: preclinical and clinical considerations. Expert Rev Anticancer Ther 2015,15(7),829-837","journal-title":"Expert Rev Anticancer Ther"},{"key":"ref=30","doi-asserted-by":"publisher","first-page":"172513","DOI":"10.1016\/j.ejphar.2019.172513","volume":"859","author":"Negrette-Guzm\u00e1n M.","year":"2019","unstructured":"Negrette-Guzm\u00e1n M.; Combinations of the antioxidants sulforaphane or curcumin and the conventional antineoplastics cisplatin or doxorubicin as prospects for anticancer chemotherapy. Eur J Pharmacol 2019,859,172513","journal-title":"Eur J Pharmacol"},{"key":"ref=31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.toxlet.2019.02.013","volume":"307","author":"Songbo M.","year":"2019","unstructured":"Songbo M.; Lang H.; Xinyong C.; Bin X.; Ping Z.; Liang S.; Oxidative stress injury in doxorubicin-induced cardiotoxicity. Toxicol Lett 2019,307,41-48","journal-title":"Toxicol Lett"},{"key":"ref=32","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1186\/s12885-015-1407-6","volume":"15","author":"Conway A.","year":"2015","unstructured":"Conway A.; McCarthy A.L.; Lawrence P.; Clark R.A.; The prevention, detection and management of cancer treatment-induced cardiotoxicity: a meta-review. BMC Cancer 2015,15,366","journal-title":"BMC Cancer"},{"key":"ref=33","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1097\/MAJ.0000000000000432","volume":"349","author":"Sun F.","year":"2015","unstructured":"Sun F.; Qi X.; Geng C.; Li X.; Dexrazoxane protects breast cancer patients with diabetes from chemotherapy-induced cardiotoxicity. Am J Med Sci 2015,349(5),406-412","journal-title":"Am J Med Sci"},{"key":"ref=34","doi-asserted-by":"publisher","first-page":"224","DOI":"10.2174\/1871529X18666180406125225","volume":"18","author":"Yeung P.K.","year":"2018","unstructured":"Yeung P.K.; Purcell C.; Akhoundi F.; Agu R.U.; Adenosine and Adenosine 5\u2032-triphosphate Catabolism in Systemic Blood as a Potential Biomarker for Doxorubicin Cardiotoxicity in an Experimental Rat Model in vivo. Cardiovasc Hematol Disord Drug Targets 2018,18(3),224-233","journal-title":"Cardiovasc Hematol Disord Drug Targets"},{"key":"ref=35","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/10715760802673008","volume":"43","author":"Tatlidede E.","year":"2009","unstructured":"Tatlidede E.; Sehirli O.; Velio\u011flu-O\u011f\u00fcnc A.; Cetinel S.; Ye\u011fen B.C.; Yarat A.; S\u00fcleymano\u011flu S.; Sener G.; Resveratrol treatment protects against doxorubicin-induced cardiotoxicity by alleviating oxidative damage. Free Radic Res 2009,43(3),195-205","journal-title":"Free Radic Res"},{"key":"ref=36","first-page":"59","volume":"16","author":"Starr L.","year":"2012","unstructured":"Starr L.; Purcell C.; Yeung P.; Effect of doxorubicin on cardiovascular hemodynamic and RBC concentrations of ATP in rats in vivo. Curr Top Pharmacol 2012,16,59","journal-title":"Curr Top Pharmacol"},{"key":"ref=37","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1016\/j.jpba.2008.01.020","volume":"47","author":"Yeung P.","year":"2008","unstructured":"Yeung P.; Ding L.; Casley W.L.; HPLC assay with UV detection for determination of RBC purine nucleotide concentrations and application for biomarker study in vivo. J Pharm Biomed Anal 2008,47(2),377-382","journal-title":"J Pharm Biomed Anal"},{"key":"ref=38","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00007691-200004000-00007","volume":"22","author":"Feng J.D.","year":"2000","unstructured":"Feng J.D.; Yeung P.K.; A simple high-performance liquid chromatography assay for simultaneous measurement of adenosine, guanosine, and the oxypurine metabolites in plasma. Ther Drug Monit 2000,22(2),177-183","journal-title":"Ther Drug Monit"},{"key":"ref=39","first-page":"39","volume":"15","author":"Yeung P.","year":"2011","unstructured":"Yeung P.; Narayanan S.; Hemodynamic effects of single dose of cladribine in a restrained rat model. Curr Top Pharmacol 2011,15(1),39","journal-title":"Curr Top Pharmacol"},{"key":"ref=40","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1111\/jce.12252","volume":"24","author":"Elayi C.S.","year":"2013","unstructured":"Elayi C.S.; Di Biase L.; Bai R.; Burkhardt J.D.; Mohanty P.; Santangeli P.; Sanchez J.; Hongo R.; Gallinghouse G.J.; Horton R.; Bailey S.; Beheiry S.; Natale A.; Administration of isoproterenol and adenosine to guide supplemental ablation after pulmonary vein antrum isolation. J Cardiovasc Electrophysiol 2013,24(11),1199-1206","journal-title":"J Cardiovasc Electrophysiol"},{"key":"ref=41","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1001\/jama.2020.1707","volume":"323","author":"Tap W.D.","year":"2020","unstructured":"Tap W.D.; Wagner A.J.; Sch\u00f6ffski P.; Martin-Broto J.; Krarup-Hansen A.; Ganjoo K.N.; Yen C.C.; Abdul Razak A.R.; Spira A.; Kawai A.; Le Cesne A.; Van Tine B.A.; Naito Y.; Park S.H.; Fedenko A.; P\u00e1pai Z.; Soldatenkova V.; Shahir A.; Mo G.; Wright J.; Jones R.L.; Effect of Doxorubicin Plus Olaratumab vs Doxorubicin Plus Placebo on Survival in Patients With Advanced Soft Tissue Sarcomas: The ANNOUNCE Randomized Clinical Trial. JAMA ANNOUNCE Investigators2020,323(13),1266-1276","journal-title":"JAMA"},{"key":"ref=42","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.ejphar.2014.01.065","volume":"728","author":"Mantawy E.M.","year":"2014","unstructured":"Mantawy E.M.; El-Bakly W.M.; Esmat A.; Badr A.M.; El-Demerdash E.; Chrysin alleviates acute doxorubicin cardiotoxicity in rats via suppression of oxidative stress, inflammation and apoptosis. Eur J Pharmacol 2014,728,107-118","journal-title":"Eur J Pharmacol"},{"key":"ref=43","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.cbi.2014.06.010","volume":"219","author":"Agrawal Y.O.","year":"2014","unstructured":"Agrawal Y.O.; Sharma P.K.; Shrivastava B.; Arya D.S.; Goyal S.N.; Hesperidin blunts streptozotocin-isoproternol induced myocardial toxicity in rats by altering of PPAR-\u03b3 receptor. Chem Biol Interact 2014,219,211-220","journal-title":"Chem Biol Interact"},{"key":"ref=44","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1186\/s12882-015-0033-5","volume":"16","author":"Kurra V.","year":"2015","unstructured":"Kurra V.; Vehmas T.; Er\u00e4ranta A.; Jokihaara J.; Pirttiniemi P.; Ruskoaho H.; Tokola H.; Niemel\u00e4 O.; Mustonen J.; P\u00f6rsti I.; Effects of oxonic acid-induced hyperuricemia on mesenteric artery tone and cardiac load in experimental renal insufficiency. BMC Nephrol 2015,16,35","journal-title":"BMC Nephrol"},{"key":"ref=45","first-page":"5","volume":"10","author":"Pospieszna B.","year":"2019","unstructured":"Pospieszna B.; Kusy K.; The Effect of Training on Erythrocyte Energy Status and Plasma Purine Metabolites in Athletes: Metabolites. 2019,10(1),5"},{"key":"ref=46","doi-asserted-by":"publisher","first-page":"263","DOI":"10.2165\/00002018-200022040-00002","volume":"22","author":"Pai V.B.","year":"2000","unstructured":"Pai V.B.; Nahata M.C.; Cardiotoxicity of chemotherapeutic agents: incidence, treatment and prevention. Drug Saf 2000,22(4),263-302","journal-title":"Drug Saf"},{"key":"ref=47","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"Albini A.","year":"2010","unstructured":"Albini A.; Pennesi G.; Donatelli F.; Cammarota R.; De Flora S.; Noonan D.M.; Cardiotoxicity of anticancer drugs: the need for cardio-oncology and cardio-oncological prevention. J Natl Cancer Inst 2010,102(1),14-25","journal-title":"J Natl Cancer Inst"},{"key":"ref=48","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"Yeh E.T.","year":"2009","unstructured":"Yeh E.T.; Bickford C.L.; Cardiovascular complications of cancer therapy: incidence, pathogenesis, diagnosis, and management. J Am Coll Cardiol 2009,53(24),2231-2247","journal-title":"J Am Coll Cardiol"},{"key":"ref=49","doi-asserted-by":"publisher","first-page":"H1453","DOI":"10.1152\/ajpheart.00554.2015","volume":"309","author":"Varga Z.V.","year":"2015","unstructured":"Varga Z.V.; Ferdinandy P.; Liaudet L.; Pacher P.; Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 2015,309(9),H1453-H1467","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"ref=50","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2478\/acph-2013-0038","volume":"63","author":"Feridooni T.","year":"2013","unstructured":"Feridooni T.; Mac Donald C.; Shao D.; Yeung P.; Agu R.U.; Cytoprotective potential of anti-ischemic drugs against chemotherapy-induced cardiotoxicity in H9c2 myoblast cell line. Acta Pharm 2013,63(4),493-503","journal-title":"Acta Pharm"},{"key":"ref=51","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1016\/j.biochi.2011.02.015","volume":"94","author":"Ghibu S.","year":"2012","unstructured":"Ghibu S.; Delemasure S.; Richard C.; Guilland J.C.; Martin L.; Gambert S.; Rochette L.; Vergely C.; General oxidative stress during doxorubicin-induced cardiotoxicity in rats: absence of cardioprotection and low antioxidant efficiency of alpha-lipoic acid. Biochimie 2012,94(4),932-939","journal-title":"Biochimie"},{"key":"ref=52","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1188\/08.CJON.627-638","volume":"12","author":"Viale P.H.","year":"2008","unstructured":"Viale P.H.; Yamamoto D.S.; Cardiovascular toxicity associated with cancer treatment. Clin J Oncol Nurs 2008,12(4),627-638","journal-title":"Clin J Oncol Nurs"},{"key":"ref=53","doi-asserted-by":"publisher","first-page":"1361","DOI":"10.1002\/ptr.2688","volume":"23","author":"Tiwari R.","year":"2009","unstructured":"Tiwari R.; Mohan M.; Kasture S.; Maxia A.; Ballero M.; Cardioprotective potential of myricetin in isoproterenol-induced myocardial infarction in Wistar rats. Phytother Res 2009,23(10),1361-1366","journal-title":"Phytother Res"},{"key":"ref=54","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.28480","author":"Rahnavard M.","year":"2019","unstructured":"Rahnavard M.; Hassanpour M.; Ahmadi M.; Heidarzadeh M.; Amini H.; Javanmard M.Z.; Nouri M.; Rahbarghazi R.; Safaie N.; Curcumin ameliorated myocardial infarction by inhibition of cardiotoxicity in the rat model. J Cell Biochem Online ahead of print2019","journal-title":"J Cell Biochem"},{"key":"ref=55","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1080\/10715762.2018.1554901","volume":"53","author":"Feng L.","year":"2019","unstructured":"Feng L.; Ren J.; Li Y.; Yang G.; Kang L.; Zhang S.; Ma C.; Li J.; Liu J.; Yang L.; Qi Z.; Resveratrol protects against isoproterenol induced myocardial infarction in rats through VEGF-B\/AMPK\/eNOS\/NO signalling pathway. Free Radic Res 2019,53(1),82-93","journal-title":"Free Radic Res"},{"key":"ref=56","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1242\/jeb.023697","volume":"212","author":"Jensen F.B.","year":"2009","unstructured":"Jensen F.B.; The dual roles of red blood cells in tissue oxygen delivery: oxygen carriers and regulators of local blood flow. J Exp Biol 2009,212(Pt 21),3387-3393","journal-title":"J Exp Biol"},{"key":"ref=57","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1093\/cvr\/26.1.40","volume":"26","author":"Bergfeld G.R.","year":"1992","unstructured":"Bergfeld G.R.; Forrester T.; Release of ATP from human erythrocytes in response to a brief period of hypoxia and hypercapnia. Cardiovasc Res 1992,26(1),40-47","journal-title":"Cardiovasc Res"},{"key":"ref=58","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1086\/651584","volume":"83","author":"L\u00f3pez-Barneo J.","year":"2010","unstructured":"L\u00f3pez-Barneo J.; Nurse C.A.; Nilsson G.E.; Buck L.T.; Gassmann M.; Bogdanova A.Y.; First aid kit for hypoxic survival: sensors and strategies. Physiol Biochem Zool 2010,83(5),753-763","journal-title":"Physiol Biochem Zool"},{"key":"ref=59","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.biocel.2014.01.014","volume":"49","author":"Panayiotou C.","year":"2014","unstructured":"Panayiotou C.; Solaroli N.; Karlsson A.; The many isoforms of human adenylate kinases. Int J Biochem Cell Biol 2014,49,75-83","journal-title":"Int J Biochem Cell Biol"},{"key":"ref=60","doi-asserted-by":"publisher","first-page":"13864","DOI":"10.1038\/ncomms13864","volume":"7","author":"Kaur H.","year":"2016","unstructured":"Kaur H.; Lakatos-Karoly A.; Vogel R.; N\u00f6ll A.; Tamp\u00e9 R.; Glaubitz C.; Coupled ATPase-adenylate kinase activity in ABC transporters. Nat Commun 2016,7,13864","journal-title":"Nat Commun"},{"key":"ref=61","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.3390\/ijms10041729","volume":"10","author":"Dzeja P.","year":"2009","unstructured":"Dzeja P.; Terzic A.; Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci 2009,10(4),1729-1772","journal-title":"Int J Mol Sci"},{"key":"ref=62","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10863-016-9687-3","volume":"48","author":"Klepinin A.","year":"2016","unstructured":"Klepinin A.; Ounpuu L.; Guzun R.; Chekulayev V.; Timohhina N.; Tepp K.; Shevchuk I.; Schlattner U.; Kaambre T.; Simple oxygraphic analysis for the presence of adenylate kinase 1 and 2 in normal and tumor cells. J Bioenerg Biomembr 2016,48(5),531-548","journal-title":"J Bioenerg Biomembr"},{"key":"ref=63","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1016\/j.pharmthera.2013.11.003","volume":"142","author":"Ertracht O.","year":"2014","unstructured":"Ertracht O.; Malka A.; Atar S.; Binah O.; The mitochondria as a target for cardioprotection in acute myocardial ischemia. Pharmacol Ther 2014,142(1),33-40","journal-title":"Pharmacol Ther"}],"container-title":["Drug Metabolism Letters"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/eurekaselect.com\/article\/download\/187094","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.eurekaselect.com\/187094\/article","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/eurekaselect.com\/article\/download\/187094","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T14:25:54Z","timestamp":1634480754000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.eurekaselect.com\/187094\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,5]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,5,5]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1872312814666201022103802","relation":{},"ISSN":["1872-3128"],"issn-type":[{"type":"print","value":"1872-3128"}],"subject":[],"published":{"date-parts":[[2021,5,5]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2020-06-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-18","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-08-30","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-05-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}